title: A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
abstract: As docetaxel is known to have significant antineoplastic activity against breast and ovarian cancer, we explored its application as a peripheral blood stem cell mobilizing agent in 33 women with stage lll-IV ovarian carcinoma (n = 10) or stage ll-lV breast cancer (n = 23) who were in preparation for high-dose chemotherapy. Eleven patients had bone and/or bone marrow involvement with their disease. The median number of prior regimens received before mobilization was two (range 1-3). The three dose levels administered were 100 mg/m(2), 110 mg/m(2) and 120 mg/m(2). Patients received one dose of docetaxel in the outpatient setting followed by G-CSF (10 microg/kg/day) starting 4 days after docetaxel administration. Leukapheresis commenced when WBC >1.0 x 10(9)/l or when the WBC began to rise after reaching a nadir. Ninety-seven percent of patients began leukapheresis within 7-9 days after receiving docetaxel (range 7-10 days). The collection goal was >/=2 x 10(6) CD34(+) cells/kg. Twenty-seven (82%) patients reached this goal in a median of 2 leukapheresis days (range 1-3). No grade 2-4 nonhematologic toxicities were noted. Thirteen patients (55%) showed a WBC nadir >1.0 x 10(9)/l. None of the patients experienced neutropenic fever or required blood or platelet transfusion support. In conclusion, docetaxel + G-CSF is an effective, well-tolerated regimen for PBPC mobilization which can be safely administered in the outpatient setting with minimal toxicity.
authors.affiliation: The University of Chicago, Division of Hematology/Oncology, Chicago, IL, USA.
authors.forename: G G
authors.initials: GG
authors.lastname: Laport
authors.forename: G F
authors.initials: GF
authors.lastname: Fleming
authors.forename: S
authors.initials: S
authors.lastname: Waggoner
authors.forename: T M
authors.initials: TM
authors.lastname: Zimmerman
authors.forename: D L
authors.initials: DL
authors.lastname: Grinblatt
authors.forename: S F
authors.initials: SF
authors.lastname: Williams
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000592:standards / Q000633:toxicity; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D000077143:Docetaxel; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000633:toxicity; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007937:Leukapheresis; D007958:Leukocyte Count; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000592:standards / Q000633:toxicity; D011994:Recombinant Proteins; D013234:Stem Cells / Q000276:immunology; D043823:Taxoids
chemical_list: D018952:Antigens, CD34; D000972:Antineoplastic Agents, Phytogenic; D011994:Recombinant Proteins; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; D017239:Paclitaxel; D000069585:Filgrastim